Cardiovascular disease is presently the number one cause of death worldwide. Current stents used to treat cardiovascular disease have a litany of unacceptable shortcomings: adverse clinical events include restenosis, neointimal hyperplasia, thrombosis, inflammation, and poor re-endothelialization. We have developed a biocompatible, multifunctional, peptide amphiphile-based nanomatrix coating for stents. In this study, we evaluated the ability of the nanomatrix coated stent to simultaneously address the issues facing current stents under physiological flow conditions in vitro. We found that the nanomatrix coated stent could increase endothelial cell migration, adhesion, and proliferation (potential for re-endothelialization), discourage smooth muscle cell migration and adhesion (potential to reduce neointimal hyperplasia and restenosis), and decrease both platelet activation and adhesion (potential to prevent thrombosis) as well as monocyte adhesion (potential to attenuate inflammatory responses) under physiological flow conditions in vitro. These promising results demonstrate the potential clinical utility of this nanomatrix stent coating, and highlight the importance of biocompatibility, multifunctionality, and bioactivity in cardiovascular device design.
Bibliographical noteFunding Information:
This study was supported by NIH T-32 Cardiovascular Pathophysiology Training Fellowship (5T32HL007918-17 to G.A.), Alabama EPSCoR GRSP Fellowship (to G.A.), NIH (1R01HL125391, 1R43NS095455, 1R43DK109789, 2R44DK109789-02 to H.J.), NIH (R01HL127759, 1DP3DK108245, R01HL129511 to Y.Y. and H.J.), NIH (1R01HL128695 to J.K.), and in part by a grant to the University of Alabama at Birmingham from the Howard Hughes Medical Institute through the Med into Grad Initiative.
© 2017 American Chemical Society.
All Science Journal Classification (ASJC) codes
- Biomedical Engineering